Voluntary nationwide recall: Ocaliva (Intercept – September)
Oct. 2025Pharmacy Updates
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).
This drug is being withdrawn because of concerns regarding the benefits versus the risks of taking it. This voluntary withdrawal followed a request from the U.S. Food and Drug Administration (FDA) to withdraw the drug.
If you are currently prescribed Ocaliva, you should consult your health care professional before making any changes. Intercept will provide additional information to support health care professionals and patients as it works with FDA on the transition process.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Patients can call Intercept’s Patient Support Services (Interconnect) at 1-844-622-4278. TTY users should call 711.
- Providers can contact Intercept Medical Information at medinfo@interceptpharma.com or call 1-844-782-4278.
- Visit Intercept’s website: OCALIVA: Withdrawal Process - Intercept Pharmaceuticals
Recent Announcements
UPMC Dental Advantage celebrates 15-years of growth
From pilot program to now serving all product linesJan. 2026What's New
Provider Directory Updates and Required Attestation
As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).Jan. 2026Important Notices
Important: Expedited appeals fax requirement
Please remember that you must adhere to the designated process for submitting expedited appeals to have them processed in a timely manner. Follow these guidelines to help you successfully submit expedited appeals:Jan. 2026Important Notices